# Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]

> **NCT03428607** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 26 (actual)

## Conditions studied

- SCLC

## Interventions

- **DRUG:** AZD6738
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03428607
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-17
- **Primary completion:** 2021-01-15
- **Final completion:** 2021-01-15
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03428607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03428607, "Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03428607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*